Skip to main content
ATOS logo

ATOS · Atossa Therapeutics, Inc.

Track ATOS — free
$1.65 -0.10 (-5.71%)
Market Cap
$15.92M
Shares
9.98M
Volume · Nov 20 48.93K Avg daily vol (3M) 67.59K

Price & Indicators

 

Key stats

Close
$1.60
Fri 20 Nov
Open
$1.72
Fri 20 Nov
Average volume, 30 days
73K
shares a session
Short interest
527K
5.3% of shares · 7.6 days to cover
Day range
$1.59$1.72
Open $1.72 Close $1.60
52-week closing range
$1.60$13.50
Close $1.60 88.2% under the high
Short volume, last session
60%
Last earnings
Mar 25, 2025
Latest filing
10-Q · Nov 10
Price history
Jan 2020 to Nov 2026

Up next

call held Aug 14, 2023

Latest documents

2026
Nov 10
Current report 8-K
CVR shares 25% of voucher proceeds capped at $50 million

Atossa Therapeutics, Inc. said CVR holders are entitled to 25% of net proceeds from monetizing its first priority review voucher, capped at $50 million. Third-quarter operating expenses were $5.9 million, down from $9.3 million.

Financial results
3 source passages
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results for the third quarter ended September 30, 2026 and provided an update on recent corporate developments. CVR holders will be entitled, in the aggregate, to 25% of the net proceeds from the sale or other monetization of the first qualifying U.S. Food and Drug Administration (FDA) priority review voucher (PRV) awarded to Atossa, subject to a maximum aggregate payment of $50 million. Total operating expenses were $5.9 million and $24.5 million for the three and nine months ended September 30, 2026, respectively, which represented a decrease of $3.4 million and $1.2 million from total operating expenses for the three and nine months ended September 30, 2025, which were $9.3 million and $25.7 million, respectively. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Z-Endoxifen advances in four Phase 2 trials

Atossa Therapeutics said (Z)-endoxifen is being investigated in four Phase 2 trials. Nine-month 2026 operating expenses were $24.5 million, down from $25.7 million, and net cash used in operating activities was (24,745) thousand.

Net loss $5.64M Diluted EPS -$0.56
Read from the MD&A section
3 source passages
(Z)-Endoxifen is currently being investigated in four Phase 2 trials, including the completed Karisma trial: Total operating expenses were $5.9 million and $24.5 million for the three and nine months ended September 30, 2026, respectively, which represented a decrease of $3.4 million and $1.2 million from total operating expenses for the three and nine months ended September 30, 2025, which were $9.3 million and $25.7 million, respectively. Net cash used in operating activities | (24,745) | (19,223) Open the document at this passage
Oct 9
Current report 8-K Events of Oct 8
Entered into a material agreement, Change to shareholders' rights, Other events

Atossa Therapeutics declared one stapled contingent value right per common share, payable from 25% of net proceeds of the first FDA priority review voucher awarded by December 31, 2036, up to $50 million. No voucher has been awarded.

Read from the first part of this long document
Sep 29
Current report 8-K
Other events

Atossa Therapeutics approved a plan to issue one contingent value right per common share, entitling holders to 25% of net proceeds from monetizing its first qualifying rare pediatric disease priority review voucher, subject to a $50 million aggregate payment cap.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$34.66M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-202.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$20.57M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.3%
Latest settlement · 7.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −54%
below
Price vs 50-day avg −30%
below
RSI (14) 27
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −39%
trailing
6-month return −67%
trailing
YTD return −82%
this year
Relative strength −58%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+9% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.28% of shares out · ▼ -22.9% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
36 holders — mid 3-yr range
Squeeze score 48
elevated · 0–100
Fundamentals
Weak
Revenue growth −96%
Y/Y
Gross margin -7432%
contracting
EPS growth −33%
Y/Y
Free cash flow $-29.8M
Buyback $10.0M
authorized
Balance sheet $41.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −88%
past year
ATR 11.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−54% Bearish
Price vs 50-day avg
−30% Bearish
RSI (14)
27 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+9% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.28% of shares out · ▼ -22.9% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
36 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $14
vs 200-day avg -54% vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATOS
Atossa Therapeutics, Inc.
this stock
$15.92M — -95.6% — 5.3%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
36
% held
9.7%
Net QoQ
-374.3K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
14
View
Short & Settlement
Short Interest Falling
Shares short
526.8K
Days to cover
7.6d
Change
-156.7K sh
View
Short Volume
Short vol %
60%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
165
Value
$422
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
51.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-34.8M
EPS diluted
$-4.04
View
Buybacks
Authorized
$10.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 10, 2026
This year
24

Atossa Therapeutics said (Z)-endoxifen is being investigated in four Phase 2 trials. Nine-month 2026 operating expenses were $24.5 million, down from $25.7 million, and net cash used in operating activities was (24,745) thousand.

View
Earnings & Events
Webcasts
Last webcast
May 19, 2026
View
Investor Relations
Latest news
Atossa Therapeutics Reports Third…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
ATOS -18.6% -38.7% -67.1% -26.5% -82.0%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -10.1% -29.4% -57.9% -17.8% -83.1%

Capital returns

Buyback program · as of Jun 27, 2023
Authorized
$10.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1488039 CUSIP 04962H704 13F (30d) 61 filings 35 filers Visit website Investor relations